Search research articles
Contact Us
Filters
Showing results (381-390 of 411) with videos related to
Page
of 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
BMC Cancer
|
July 16, 2016
The Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Recruitment, Baseline Assessment, and Description of the First 500 Participants
Kerry S Courneya, Margaret L McNeely, S Nicole Culos-Reed, et al.
Journal of Translational Medicine
|
May 7, 2024
Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition
Erwan Beauchamp, Jay M Gamma, Christopher R Cromwell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
J R Mackey, T Pieńkowski, J Crown, et al.
Blood
|
September 30, 2004
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations
John R Mackey, Carlos M Galmarini, Kathryn A Graham, et al.
Cell Reports. Medicine
|
November 10, 2021
Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patient
Zhongyi Zhu, Weiwei Wang, Feng Lin, et al.
Cancers
|
November 23, 2019
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
Jerome Raffenne, Remy Nicolle, Francesco Puleo, et al.
Breast Cancer Research : BCR
|
November 7, 2013
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
Bella Pajares, Marina Pollán, Miguel Martín, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
John R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Cancer Causes & Control : CCC
|
January 22, 2022
The Alberta moving beyond breast cancer (AMBER) cohort study: baseline description of the full cohort
Christine M Friedenreich, Jeff K Vallance, Margaret L McNeely, et al.
Page
of 42
Search research articles
Search
Showing results (381-390 of 411) with videos related to
Sort By:
Page
of 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
BMC Cancer
|
July 16, 2016
The Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Recruitment, Baseline Assessment, and Description of the First 500 Participants
Kerry S Courneya, Margaret L McNeely, S Nicole Culos-Reed, et al.
Journal of Translational Medicine
|
May 7, 2024
Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition
Erwan Beauchamp, Jay M Gamma, Christopher R Cromwell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
J R Mackey, T Pieńkowski, J Crown, et al.
Blood
|
September 30, 2004
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations
John R Mackey, Carlos M Galmarini, Kathryn A Graham, et al.
Cell Reports. Medicine
|
November 10, 2021
Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patient
Zhongyi Zhu, Weiwei Wang, Feng Lin, et al.
Cancers
|
November 23, 2019
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
Jerome Raffenne, Remy Nicolle, Francesco Puleo, et al.
Breast Cancer Research : BCR
|
November 7, 2013
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
Bella Pajares, Marina Pollán, Miguel Martín, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
John R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Cancer Causes & Control : CCC
|
January 22, 2022
The Alberta moving beyond breast cancer (AMBER) cohort study: baseline description of the full cohort
Christine M Friedenreich, Jeff K Vallance, Margaret L McNeely, et al.
Page
of 42